Camurus AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAMRF research report →
About the company
Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders.
- CEO
- Sven Fredrik Tiberg
- IPO
- 2017
- Employees
- 277
- HQ
- Lund, CAM, SE
Price Chart
- Market Cap
- $3.63B
- P/E
- 49.93
- P/S
- 15.37
- P/B
- 7.70
- EV/EBITDA
- 34.42
- Div Yield
- 0.00%
- Gross Margin
- 92.53%
- Op Margin
- 36.74%
- Net Margin
- 30.45%
- ROE
- 16.39%
- ROIC
- 14.20%
- Revenue
- $2.27B · 21.30%
- Net Income
- $735.57M · 71.70%
- EPS
- $12.42 · 68.06%
- Op Income
- $873.93M
- FCF YoY
- 103.78%
- 52W High
- $71.00
- 52W Low
- $54.00
- 50D MA
- $60.37
- 200D MA
- $62.98
- Beta
- 0.52
- Avg Volume
- 87
Get TickerSpark's AI analysis on CAMRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our CAMRF coverage
Recent articles, reports, and earnings notes.
No research on CAMRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CAMRF report →Similar companies
Peers in the same neighborhood.